Arbutus Biopharma (NASDAQ:ABUS) Trading Up 6.3% - Here's What Happened

Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) shares were up 6.3% on Thursday . The stock traded as high as $3.44 and last traded at $3.39. Approximately 119,890 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 1,021,157 shares. The stock had previously closed at $3.19.

Analyst Ratings Changes

ABUS has been the subject of several research analyst reports. StockNews.com downgraded shares of Arbutus Biopharma from a "hold" rating to a "sell" rating in a report on Thursday. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a report on Tuesday, January 21st. Finally, Chardan Capital reaffirmed a "buy" rating and set a $5.00 price target (up from $4.50) on shares of Arbutus Biopharma in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $5.50.

Arbutus Biopharma Price Performance

The firm's 50-day simple moving average is $3.33 and its 200 day simple moving average is $3.63. The firm has a market capitalization of $628.17 million, a price-to-earnings ratio of -7.66 and a beta of 1.93.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. bought a new stake in shares of Arbutus Biopharma during the fourth quarter worth about $236,000. Charles Schwab Investment Management Inc. increased its position in Arbutus Biopharma by 218.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company's stock worth $4,667,000 after buying an additional 831,663 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Arbutus Biopharma during the 3rd quarter valued at approximately $754,000. Barclays PLC raised its stake in shares of Arbutus Biopharma by 466.3% during the 3rd quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company's stock valued at $1,047,000 after purchasing an additional 223,995 shares during the period. Finally, State Street Corp increased its holdings in Arbutus Biopharma by 50.2% during the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company's stock worth $16,967,000 after acquiring an additional 1,472,652 shares during the period. Institutional investors and hedge funds own 43.79% of the company's stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads